Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiviral therapy: hepatitis B.

M R Jacyna1, H C Thomas

  • 1Department of Medicine and Hepatology, St Marys Hospital Medical School, Imperial College, University of London.

British Medical Bulletin
|April 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference.

Journal of viral hepatitis·2016
Same author

Depressive symptoms in chronic hepatitis C are associated with plasma apolipoprotein E deficiency.

Metabolic brain disease·2014
Same author

Successful control of nosocomial transmission of the USA300 clone of community-acquired meticillin-resistant Staphylococcus aureus in a UK paediatric burns centre.

The Journal of hospital infection·2013
Same author

Cerebral microglial activation in patients with hepatitis C: in vivo evidence of neuroinflammation.

Journal of viral hepatitis·2012
Same author

A comparison of 31P magnetic resonance spectroscopy and microbubble-enhanced ultrasound for characterizing hepatitis c-related liver disease.

Journal of viral hepatitis·2011
Same author

The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*.

Journal of viral hepatitis·2011

Antiviral therapies can help chronic hepatitis B virus (HBV) infection, but treatment options like adenosine arabinoside monophosphate and acyclovir have limitations. Alpha-interferons offer a promising approach for adults, with ongoing research for infants.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic hepatitis B virus (HBV) infection can lead to liver cirrhosis.
  • Antiviral therapy aims to control HBV replication and prevent disease progression.
  • Previous treatments like adenosine arabinoside monophosphate and acyclovir have shown limited efficacy or significant toxicity.

Purpose of the Study:

  • To review current antiviral therapies for chronic HBV infection.
  • To evaluate the effectiveness and limitations of different antiviral agents.
  • To identify optimal treatment strategies based on patient demographics and infection acquisition time.

Main Methods:

  • Review of existing literature on antiviral therapies for HBV.
  • Analysis of clinical trial data for agents including adenosine arabinoside monophosphate, acyclovir, and interferons.

Related Experiment Videos

  • Comparison of treatment outcomes based on patient age and method of HBV acquisition.

    • Main Results:

    • Adenosine arabinoside monophosphate inhibits HBV replication but causes neuromuscular toxicity.
    • Acyclovir is safe but ineffective in eliminating HBV from the liver.
    • Alpha-interferons (lymphoblastoid or recombinant) provide up to 50% long-term HBV replication inhibition in adults with minor side effects.
    • Alpha-interferon monotherapy is ineffective for HBV acquired from birth.

    Conclusions:

    • Alpha-interferons represent the current best option for adult HBV infection, offering significant long-term viral inhibition.
    • Prednisolone pre-treatment followed by alpha-interferon is being evaluated for patients infected from birth.
    • Further research is needed to optimize treatment for all patient groups with chronic HBV.